These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
259 related articles for article (PubMed ID: 32582101)
1. Good Manufacturing Practice (GMP) Compliance for Phage Therapy Medicinal Products. Bretaudeau L; Tremblais K; Aubrit F; Meichenin M; Arnaud I Front Microbiol; 2020; 11():1161. PubMed ID: 32582101 [TBL] [Abstract][Full Text] [Related]
2. Past and Future of Phage Therapy and Phage-Derived Proteins in Patients with Bone and Joint Infection. Ferry T; Kolenda C; Briot T; Souche A; Lustig S; Josse J; Batailler C; Pirot F; Medina M; Leboucher G; Laurent F; On Behalf Of The Lyon Bji Study Group ; On Behalf Of The PHAGEinLYON Study Group Viruses; 2021 Dec; 13(12):. PubMed ID: 34960683 [TBL] [Abstract][Full Text] [Related]
3. The Future of Clinical Phage Therapy in the United Kingdom. Jones JD; Trippett C; Suleman M; Clokie MRJ; Clark JR Viruses; 2023 Mar; 15(3):. PubMed ID: 36992430 [TBL] [Abstract][Full Text] [Related]
4. Good Manufacturing Practices (GMP) manufacturing of advanced therapy medicinal products: a novel tailored model for optimizing performance and estimating costs. Abou-El-Enein M; Römhild A; Kaiser D; Beier C; Bauer G; Volk HD; Reinke P Cytotherapy; 2013 Mar; 15(3):362-83. PubMed ID: 23579061 [TBL] [Abstract][Full Text] [Related]
5. Quality and safety requirements for sustainable phage therapy products. Pirnay JP; Blasdel BG; Bretaudeau L; Buckling A; Chanishvili N; Clark JR; Corte-Real S; Debarbieux L; Dublanchet A; De Vos D; Gabard J; Garcia M; Goderdzishvili M; Górski A; Hardcastle J; Huys I; Kutter E; Lavigne R; Merabishvili M; Olchawa E; Parikka KJ; Patey O; Pouilot F; Resch G; Rohde C; Scheres J; Skurnik M; Vaneechoutte M; Van Parys L; Verbeken G; Zizi M; Van den Eede G Pharm Res; 2015 Jul; 32(7):2173-9. PubMed ID: 25585954 [TBL] [Abstract][Full Text] [Related]
6. GMP-Grade Methods for Cardiac Progenitor Cells: Cell Bank Production and Quality Control. Andriolo G; Provasi E; Brambilla A; Lo Cicero V; Soncin S; Barile L; Turchetto L; Radrizzani M Methods Mol Biol; 2021; 2286():131-166. PubMed ID: 33381854 [TBL] [Abstract][Full Text] [Related]
7. Good manufacturing practice for immunological veterinary medicinal products. Todd JI Rev Sci Tech; 2007 Apr; 26(1):135-45. PubMed ID: 17633298 [TBL] [Abstract][Full Text] [Related]
8. The legal framework governing the quality of (traditional) herbal medicinal products in the European Union. Kroes BH J Ethnopharmacol; 2014 Dec; 158 Pt B():449-53. PubMed ID: 25086408 [TBL] [Abstract][Full Text] [Related]
9. How to achieve safe, high-quality clinical studies with non-Medicinal Investigational Products? A practical guideline by using intra-bronchial carbon nanoparticles as case study. Berger M; Kooyman PJ; Makkee M; van der Zee JS; Sterk PJ; van Dijk J; Kemper EM Respir Res; 2016 Aug; 17(1):102. PubMed ID: 27542842 [TBL] [Abstract][Full Text] [Related]
10. Challenges of running a GMP facility for regenerative medicine in a public hospital. Viganò M; Giordano R; Lazzari L Regen Med; 2017 Oct; 12(7):803-813. PubMed ID: 29115906 [TBL] [Abstract][Full Text] [Related]
12. Robust Approaches for the Production of Active Ingredient and Drug Product for Human Phage Therapy. Mutti M; Corsini L Front Microbiol; 2019; 10():2289. PubMed ID: 31649636 [TBL] [Abstract][Full Text] [Related]
13. Potential of Therapeutic Bacteriophages in Nosocomial Infection Management. Wu N; Zhu T Front Microbiol; 2021; 12():638094. PubMed ID: 33633717 [TBL] [Abstract][Full Text] [Related]
20. Good manufacturing practice: the role of local manufacturers and competent authorities. Tomić S; Filipović Sučić A; Ilić Martinac A Arh Hig Rada Toksikol; 2010 Dec; 61(4):425-36. PubMed ID: 21183434 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]